期刊
DIABETES-METABOLISM RESEARCH AND REVIEWS
卷 21, 期 2, 页码 167-174出版社
WILEY
DOI: 10.1002/dmrr.478
关键词
combination; efficacy; long-term; metformin; pioglitazone; type 2 diabetes
Background This 52-week, randomized, double-blind study compared the efficacy and safety of metformin plus pioglitazone with the established combination of metformin plus gliclazide in type 2 diabetes mellitus. Methods Patients with poorly controlled type 2 diabetes (HbA(1c) >= 7.5% to <= 11.0%) received either pioglitazone 15 mg o.d. (titrated up to 45 mg; n = 317) or gliclazide 80 mg o.d. (titrated up to 320 mg; n = 313) and metformin at the pre-study dose. HbA(1c), fasting plasma glucose (FPG), insulin, lipids and the urinary albumin/creatinine ratio were measured. Results There were no significant differences in HbA(1c) (1% decrease in both groups) and FPG between groups. There was a decrease in fasting insulin in the pioglitazone group compared to an increase in the gliclazide group (p < 0.001). There were significantly greater improvements in triglycerides and HDL-cholesterol in the metformin plus pioglitazone group compared to the metformin plus gliclazide group (p < 0.001). Mean LDL-cholesterol decreased with metformin plus gliclazide and increased with metformin plus pioglitazone (p < 0.001); however, this increase was considerably less marked than that in HDL-cholesterol. The mean urinary albumin/creatinine ratio was reduced by 10% in the metformin plus pioglitazone group compared to an increase of 6% in the metformin plus gliclazide group (p = 0.027). The incidence of adverse events was comparable between groups and both combinations were well tolerated. Conclusions Compared to the established combination of metformin plus gliclazide, this study indicates potential benefits of addition of. pioglitazone to metformin in terms of improvements in microalbuminuria and specific abnormalities associated with diabetic dyslipidemia. Copyright (c) 2005 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据